摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-Prop-2-ynoxypyrazine

中文名称
——
中文别名
——
英文名称
2-Prop-2-ynoxypyrazine
英文别名
2-prop-2-ynoxypyrazine
2-Prop-2-ynoxypyrazine化学式
CAS
——
化学式
C7H6N2O
mdl
——
分子量
134.14
InChiKey
KVAAOJZSFCRKIY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    10
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.14
  • 拓扑面积:
    35
  • 氢给体数:
    0
  • 氢受体数:
    3

文献信息

  • PERFLUORINATED 5,6-DIHYDRO-4H-1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE
    申请人:AMGEN INC.
    公开号:US20140249104A1
    公开(公告)日:2014-09-04
    The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A 4 , A 5 , A 6 , A 8 , each of R 1 and R 2 , R 3 and R 7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III.
    本发明提供了一类新的化合物,用于调节β-分泌酶(BACE)活性。这些化合物的通用公式为I: 其中变量A4,A5,A6,A8,公式I中的R1和R2,R3和R7各自独立定义如下。本发明还提供了包含这些化合物的药物组合物,以及使用这些化合物和组合物治疗与A-β斑块形成和沉积相关的疾病和/或状况,这些疾病和/或状况是由BACE的生物活性引起的。这样的BACE介导的疾病包括,例如,阿尔茨海默病,认知缺陷,认知障碍,精神分裂症和其他中枢神经系统疾病。本发明进一步提供了公式II和III的化合物,以及其子公式的实施例,中间体和用于制备公式I-III化合物的过程和方法。
  • Cyclopropyl Fused Thiazin-2-Amine Compounds as Beta-Secretase Inhibitors and Methods of Use
    申请人:AMGEN INC.
    公开号:US20160046618A1
    公开(公告)日:2016-02-18
    The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A 4 , A 5 , A 6 , A 8 , and each of R a , R b , R 1 , R 2 , R 3 and R 7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.
    本发明提供了一类新的化合物,可用于调节β-分泌酶(BACE)活性。该化合物具有通式I:其中变量A4、A5、A6、A8和通式I中的每个Ra、Rb、R1、R2、R3和R7,在此独立地定义。本发明还提供了包含该化合物的药物组合物,并且提供了使用该化合物和组合物治疗与A-beta斑块形成和沉积相关的疾病和/或病况,这是由BACE的生物活性引起的。这种BACE介导的疾病包括,例如,阿尔茨海默病、认知缺陷、认知障碍、精神分裂症和其他中枢神经系统疾病。本发明还提供了通式II和III的化合物,以及其子式实施例、中间体和制备本发明化合物的方法。
  • CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE
    申请人:AMGEN INC.
    公开号:US20170267673A1
    公开(公告)日:2017-09-21
    The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A 4 , A 5 , A 6 , A 8 , and each of R a , R b , R 1 , R 2 , R 3 and R 7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.
  • US9296734B2
    申请人:——
    公开号:US9296734B2
    公开(公告)日:2016-03-29
  • US9550762B2
    申请人:——
    公开号:US9550762B2
    公开(公告)日:2017-01-24
查看更多